Early Termination and Withdrawal of Phase 3 Clinical Trial for Overactive Bladder Drug UIP620
Sinsin Pharmaceutical decided to early terminate and voluntarily withdraw the Phase 3 clinical trial for overactive bladder treatment UIP620
Reason for withdrawal: the trial required more subjects (target 686) and operational resources than initially expected; the company plans to pivot to a better well-aging project and pursue joint development
The trial was approved in July 2024 with a 24-month timeline, but early termination was reported to MFDS on May 22, 2026
KOSDAQ Filing Information
Filing: Major Management Matters Related to Investment Decision (Voluntary Withdrawal of Clinical Trial Plan Etc.) (Early Termination of Phase 3 Clinical Trial for Overactive Bladder Treatment UIP620)